Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Nefrologia |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002020000100031 |
Resumo: | ABSTRACT Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function. |
id |
SBN-1_5f6b38ce65380637670a4f43044af63e |
---|---|
oai_identifier_str |
oai:scielo:S0101-28002020000100031 |
network_acronym_str |
SBN-1 |
network_name_str |
Jornal Brasileiro de Nefrologia |
repository_id_str |
|
spelling |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function?Cystatin CCardiovascular DiseasesPeritoneal DialysisABSTRACT Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function.Sociedade Brasileira de Nefrologia2020-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002020000100031Brazilian Journal of Nephrology v.42 n.1 2020reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2019-0007info:eu-repo/semantics/openAccessMoreira,Carla LealCunha,LilianaCorreia,SofiaSilva,FilipaCastro,AnaTavares,JoanaCarvalho,Maria JoãoOliveira,José CarlosSantos,OlíviaCabrita,AntónioRodrigues,Anabelaeng2020-04-17T00:00:00Zoai:scielo:S0101-28002020000100031Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2020-04-17T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false |
dc.title.none.fl_str_mv |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
title |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
spellingShingle |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? Moreira,Carla Leal Cystatin C Cardiovascular Diseases Peritoneal Dialysis |
title_short |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
title_full |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
title_fullStr |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
title_full_unstemmed |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
title_sort |
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function? |
author |
Moreira,Carla Leal |
author_facet |
Moreira,Carla Leal Cunha,Liliana Correia,Sofia Silva,Filipa Castro,Ana Tavares,Joana Carvalho,Maria João Oliveira,José Carlos Santos,Olívia Cabrita,António Rodrigues,Anabela |
author_role |
author |
author2 |
Cunha,Liliana Correia,Sofia Silva,Filipa Castro,Ana Tavares,Joana Carvalho,Maria João Oliveira,José Carlos Santos,Olívia Cabrita,António Rodrigues,Anabela |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Moreira,Carla Leal Cunha,Liliana Correia,Sofia Silva,Filipa Castro,Ana Tavares,Joana Carvalho,Maria João Oliveira,José Carlos Santos,Olívia Cabrita,António Rodrigues,Anabela |
dc.subject.por.fl_str_mv |
Cystatin C Cardiovascular Diseases Peritoneal Dialysis |
topic |
Cystatin C Cardiovascular Diseases Peritoneal Dialysis |
description |
ABSTRACT Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002020000100031 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002020000100031 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/2175-8239-jbn-2019-0007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
dc.source.none.fl_str_mv |
Brazilian Journal of Nephrology v.42 n.1 2020 reponame:Jornal Brasileiro de Nefrologia instname:Sociedade Brasileira de Nefrologia (SBN) instacron:SBN |
instname_str |
Sociedade Brasileira de Nefrologia (SBN) |
instacron_str |
SBN |
institution |
SBN |
reponame_str |
Jornal Brasileiro de Nefrologia |
collection |
Jornal Brasileiro de Nefrologia |
repository.name.fl_str_mv |
Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN) |
repository.mail.fl_str_mv |
||jbn@sbn.org.br |
_version_ |
1752122065711792128 |